Parnell Strengthens Strategic Capabilities - Adds Senior Management

OVERLAND PARK, Kan., May 27, 2014 /PRNewswire/ -- Parnell, Inc. has announced an addition to its senior ranks with the appointment of Dr. Robert P. Hunter as chief scientific officer. Dr. Hunter represents the latest addition to the Parnell senior management team. 

"We are very excited to have Dr. Hunter join us as Chief Scientific Officer at an important time for our company's growth," says Robert Joseph, president and CEO. "Dr. Hunter has worked more than 20 years with major animal health companies, and his impressive accomplishments in academic research will bring invaluable experience to Parnell." 

Prior to joining the company, Dr. Hunter was a senior R&D executive for Elanco, a division of Eli Lilly and Company, for 10 years where he worked on various successful production animal and companion animal projects. Prior to joining Elanco, Dr. Hunter was an assistant professor in veterinary pharmacology in the schools of veterinary medicine of Kansas State University and Louisiana State University for five years.  Before his academic appointments, Dr. Hunter worked in the animal health division of Pfizer, Inc. for five years, had previous appointments at Krug Life Sciences, Inc. and held graduate research positions at Texas A&M University. Dr. Hunter has an impressive publication record with over 70 journal and book publications. He also serves as a scientific reviewer for over 20 journals and on committees for various industry congresses, including the American Academy of Veterinary Pharmacology and Therapeutics (AAVPT). Dr. Hunter has a bachelor's degree in animal science from Angelo State University in Texas, a master's degree in veterinary physiology from Texas A&M University and a doctorate in veterinary pharmacology from Louisiana State University.

Dr. Hunter will work with Matt Musselman, who was hired as chief commercial officer in January to direct the global sales and marketing teams in addition to Parnell's partner companies in the 14 countries it currently operates. Musselman had previously worked at Boehringer Ingelheim's animal health division for 10 years, most recently as the executive director of the companion animal division. Matt has a master's degree in animal science from the University of Illinois.

"The appointments of both these senior executive positions strengthen our strategic capabilities," says Joseph. "Matt and Rob will oversee the appointments of several additional sales, marketing, R&D, regulatory and clinical science positions in the coming months as we seek to expand our footprint in these important areas of our business."

About Parnell
Parnell is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms - iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving customers' operational efficiency and profitability. Parnell believes its value-added solutions help establish them as a business partner with customers rather than only as a commodity provider, differentiating them from competitors.

In the last decade, Parnell has significantly enhanced its core competencies across the entire pharmaceutical-value chain, including the 2012 FDA approval of its sterile manufacturing facility located in Sydney, Australia, which provides a low-cost and reliable supply of their own products.

For a list of all open positions at Parnell, visit www.animalhealthjobs.com or email [email protected].
For more information on the Company and its products, please visit www.parnell.com.

SOURCE Parnell, Inc.